wegovy is semaglutide A big win for Wegovy: Weight loss drug first in history to gain FDA approval for reducing heart risks Wegovy (semaglutide) Injector 1.7 mg/0.75

GLP-Activate does not contain synthetic GLP-1 and is not a substitute for GLP-1 agonist drugs

Clinical Evidence: What the Data Shows Phase 3 Trial Results (Zepbound Studies) The REFRAME and related trials demonstrated: Weight Loss Average: 22.5% body weight reduction at 68 weeks Range: 18-28% depending on population Significantly exceeds tirzepatide (21% at comparable doses) Body Composition Preferential loss of visceral fat (the dangerous kind) Better preservation of lean muscle vs

These medications mimic a natural hormone that helps regulate appetite, slow digestion, and support healthier blood sugar patterns

Cell 179 SchaferM

It would create a 25-foot safe zone around police, firefighters and others while they are performing their official duties